Altimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/09/24
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALTPRNewsWire • 05/09/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsBusiness Wire • 05/08/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsBusiness Wire • 05/08/24
The Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsBusiness Wire • 05/07/24
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALTBusiness Wire • 05/07/24
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominanceCNBC • 05/07/24
Pomerantz Law Firm Announces the Filing of a Class Action Against Altimmune, Inc. and Certain Officers - ALTPRNewsWire • 05/06/24
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024GlobeNewsWire • 05/02/24
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant PotentialThe Motley Fool • 04/20/24
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.The Motley Fool • 04/09/24
Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In PlaceSeeking Alpha • 03/27/24
Altimmune says weight loss drug minimized muscle loss in trial results that may set it apartCNBC • 03/27/24